Bioteque (4107) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 was NT$546,438 thousand, up 5.4% year-over-year from NT$518,563 thousand in Q1 2025.

• Net income for Q1 2026 reached NT$144,978 thousand, a 7.8% increase from NT$134,533 thousand in Q1 2025.

• Gross margin improved to 45% in Q1 2026 from 43% in Q1 2025.

• Comprehensive income for Q1 2026 was NT$153,690 thousand, up from NT$142,433 thousand in Q1 2025.

Financial highlights

• Operating profit for Q1 2026 was NT$176,013 thousand, up 10.6% year-over-year.

• Basic EPS for Q1 2026 was NT$2.09, compared to NT$1.94 in Q1 2025.

• Cash and cash equivalents stood at NT$1,189,689 thousand as of March 31, 2026.

• Total assets increased to NT$4,805,862 thousand as of March 31, 2026, from NT$4,773,329 thousand a year earlier.

• Cash flow from operating activities was NT$252,399 thousand in Q1 2026, up from NT$213,752 thousand in Q1 2025.

Outlook and guidance

• Adoption of IFRS 18 is expected in 2028, with the group evaluating its impact.

• No significant impact anticipated from other new or amended standards not yet endorsed.